Form 4: Enanta Pharma Officer Sells Shares for Tax Cover

Enanta Pharmaceuticals' VP of Finance, Harry R. Trout III, sold 542 shares of common stock at a weighted-average price of $14.23 to cover tax withholding obligations related to restricted stock unit awards.

Summary

• Harry R. Trout III, Vice President, Finance (Principal Financial Officer) and a Director of Enanta Pharmaceuticals Inc. (ENTA), reported a sale of common stock.
• On December 5, 2025, Mr. Trout disposed of 542 shares of Enanta Pharmaceuticals common stock.
• The shares were sold at a weighted-average price of $14.23 per share, with individual transactions ranging from $13.89 to $14.46.
• This sale was executed to cover withholding taxes due upon the settlement of restricted stock unit (RSU) awards granted on November 23, 2022, and November 22, 2023.
• The transaction was a 'sell to cover' and is explicitly stated as not representing a discretionary transaction by the reporting person.
• Following this transaction, Mr. Trout beneficially owns 16,348 shares of Enanta Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary 'sell to cover' for tax purposes related to RSU vesting, rather than a discretionary sale indicating a change in confidence or company outlook.

Positives

• The transaction represents the vesting and settlement of previously granted restricted stock unit awards, indicating the fulfillment of compensation incentives for the officer.

Negatives

• The sale of shares, even for tax purposes, results in a reduction of the officer's direct beneficial ownership in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation. It does not provide information that directly relates to broader industry trends or competitive landscape, but rather reflects standard practices for managing equity compensation in publicly traded biotechnology companies.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in management's view of the company's prospects.
• Employees: The vesting of RSUs is a standard component of executive compensation, aligning executive interests with long-term shareholder value.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Officer Transaction, Biotechnology, Pharmaceuticals